Next date
CS2009, First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan)
Drugs
5
in active trials · 10 in all
Trials
6 active
28 since 2021
Drugs5
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
PD-L1 antibody |
Approved in the EU | Dec 2029Phase 3 trial completes | |||
| Next date | Dec 2029 · Phase 3 trial completes | ||||
| Also tested for | Extranodal NK/T-cell Lymphoma | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | — | |||
| How it works | An antibody | ||||
| Also tested for | Hepatocellular Carcinoma | ||||
| Open drug page | |||||
PD-1/VEGF/CTLA-4 trispecific antibody |
Phase 1/2 | Dec 2026First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan) | |||
| How it works | A cancer drug that hits three targets | ||||
| Next date | Dec 2026 · First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan) · press release | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
CS5006not checked |
— |
Phase 1/2 | Jul 2029Phase 1/2 trial completes | ||
| Next date | Jul 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | Jan 2028Phase 1 trial completes | |||
| Next date | Jan 2028 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev